<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 25, 1995
-----------------------------------------------
Rhone-Poulenc Rorer Inc.
--------------------------------------------------
(Exact name of registrant as specified in its charter)
Pennsylvania 1-5851 23-1699163
- -----------------------------------------------------------------------------
(State or other juris- (Commission (IRS Employer
diction of incorporation) File Number) Identification No.)
500 Arcola Road, Collegeville, PA 19426
-------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (610)454-8000
--------------------------
- ------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
---------------------
Rhone-Poulenc Rorer Announces Management Changes, Michel
--------------------------------------------------------------------
de Rosen to Become Chief Executive Officer
----------------------------------------------------------------
In a January 25, 1995 press release, the Board of Directors of Rhone-
Poulenc Rorer announced that Michel de Rosen, President of RPR, Inc will also
become Chief Executive Officer effective April 25, 1995, the date of the Annual
Meeting of the Shareholders. Robert Cawthorn, presently Chairman and Chief
Executive Officer, will remain RPR's Chairman.
Prior to his appointment as RPR's President and Chief Operating Officer
in September 1993, Mr. de Rosen served as CEO of the Fibers and Polymers
Sector of Rhone-Poulenc SA and had previous experience as head of part of
Rhone-Poulenc's pharmaceutical business in France.
At the same time, RPR announced two other senior management
appointments. John Sedor has been appointed to Executive Vice President,
RPR. He will retain his responsibilities as President, Armour Pharmaceuticals,
RPR's plasma protein company, and, in addition, will oversee Corporate Human
Resources and Business Development. He will continue to report to Mr. de
Rosen. Timothy Rothwell will join the company as Executive Vice President,
RPR, and President, Pharmaceutical Operations. He will be responsible for
RPR's worldwide pharmaceutical business operations, excluding Armour and
Dermik. Mr. Rothwell will report to Michel de Rosen. Mr. Rothwell joins RPR
from Sandoz Pharmaceuticals Corporation, where he was most recently Senior
Vice President, Worldwide Business Development and Licensing, and before
that was CEO and President of Sandoz's US Pharmaceutical business. These
appointments are effective January 30, 1995.
- 2 -
<PAGE>
SIGNATURES
------------------------------------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
RHONE-POULENC RORER INC.
---------------------------------------
(registrant)
Dated: January 26, 1995 By: /s/ PATRICK LANGLOIS
------------------------------------
Patrick Langlois
Senior Vice President and
Chief Financial Officer
- 3 -
